González-Garibay Angélica Sofía, Sandoval Georgina, Torres-González Omar Ricardo, Bastidas-Ramírez Blanca Estela, Sánchez-Hernández Iván Moisés, Padilla-Camberos Eduardo
Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas No. 800 Col. Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.
Department of Molecular Biology and Genomics, Institute of Research on Chronic Degenerative Diseases, University Center of Health Sciences, Universidad de Guadalajara, Sierra Mojada No. 950 Col. Independencia, Guadalajara C.P. 44340, Jalisco, Mexico.
Pharmaceuticals (Basel). 2024 Aug 6;17(8):1036. doi: 10.3390/ph17081036.
Metabolic syndrome (MetS) comprises a cluster of metabolic risk factors, which include obesity, hypertriglyceridemia, high blood pressure, and insulin resistance. The purpose of this study was to evaluate the effects of laurate-bioconjugated fructans on pro- and anti-inflammatory cytokines in Wistar rats with MetS induced by a high-fat diet. Laurate-bioconjugated fructans were synthesized with agave fructans, immobilized lipase B, and vinyl laureate as the acylant. Groups were fed a standard diet (NORMAL), a high-fat diet (HFD), or a high-fat diet plus laurate-bioconjugated fructans (FL PREV) for 9 weeks. A fourth group received a high-fat diet for 6 weeks, followed by simultaneous exposure to a high-fat diet and laurate-bioconjugated fructans for 3 additional weeks (FL REV). The dose of laurate-bioconjugated fructans was 130 mg/kg. Laurate-bioconjugated fructans reduced food and energy intake, body weight, body mass index, abdominal circumference, adipose tissue, adipocyte area, serum triglycerides, insulin, insulin resistance, and C-reactive protein but they increased IL-10 protein serum levels and mRNA expression. The impact of laurate-bioconjugated fructans on zoometric and metabolic parameters supports their potential as therapeutic agents to improve obesity, obesity comorbidities, insulin resistance, type 2 diabetes mellitus, and MetS.
代谢综合征（MetS）由一系列代谢风险因素组成，包括肥胖、高甘油三酯血症、高血压和胰岛素抵抗。本研究的目的是评估月桂酸共轭果聚糖对高脂饮食诱导的Wistar大鼠中促炎和抗炎细胞因子的影响。月桂酸共轭果聚糖是由龙舌兰果聚糖、固定化脂肪酶B和月桂酸乙烯酯作为酰化剂合成的。将大鼠分为三组，分别喂食标准饮食（NORMAL）、高脂饮食（HFD）或高脂饮食加月桂酸共轭果聚糖（FL PREV），持续9周。第四组先接受6周高脂饮食，然后同时接受高脂饮食和月桂酸共轭果聚糖，持续3周（FL REV）。月桂酸共轭果聚糖的剂量为130 mg/kg。月桂酸共轭果聚糖降低了食物和能量摄入量、体重、体重指数、腹围、脂肪组织、脂肪细胞面积、血清甘油三酯、胰岛素、胰岛素抵抗和C反应蛋白，但提高了血清IL-10蛋白水平和mRNA表达。月桂酸共轭果聚糖对动物测量和代谢参数的影响支持了它们作为治疗肥胖、肥胖合并症、胰岛素抵抗、2型糖尿病和代谢综合征的治疗剂的潜力。
